# NutriBand Inc.: Form 10-Q for the period ended Oct 31, 2020

- Company: [NutriBand Inc.](/companies/ntrb.md) (CIK 1676047)
- Form: 10-Q
- Filed: 2020-12-15
- Accepted by EDGAR: Dec 15, 2020, 15:13 ET
- Period: 2020-10-31
- Accession: 0001213900-20-042751
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1676047/000121390020042751/f10q1020_nutribandinc.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1676047/000121390020042751/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-10-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-08-01 to 2020-10-31 | $391.8k | us-gaap:Revenues |
| Revenue | 9 months, 2020-02-01 to 2020-10-31 | $595.6k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2020-08-01 to 2020-10-31 | $228.8k | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2020-02-01 to 2020-10-31 | $420.6k | us-gaap:CostOfRevenue |
| Selling, general and administrative | 3 months, 2020-08-01 to 2020-10-31 | $204.0k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2020-02-01 to 2020-10-31 | $589.2k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2020-08-01 to 2020-10-31 | −$41.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2020-02-01 to 2020-10-31 | −$414.3k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2020-08-01 to 2020-10-31 | $1.6k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2020-02-01 to 2020-10-31 | $206.8k | us-gaap:InterestExpense |
| Net income | 3 months, 2020-08-01 to 2020-10-31 | −$42.6k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2020-02-01 to 2020-10-31 | −$680.6k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2020-08-01 to 2020-10-31 | −$0.01 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2020-02-01 to 2020-10-31 | −$0.12 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2020-02-01 to 2020-10-31 | −$213.9k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2020-10-31 | $193.4k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-10-31 | $323.3k | us-gaap:AssetsCurrent |
| Total assets | at 2020-10-31 | $10.1m | us-gaap:Assets |
| Current liabilities | at 2020-10-31 | $2.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-10-31 | $2.8m | us-gaap:Liabilities |
| Shareholders' equity | at 2020-10-31 | $7.3m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 23,561 characters.

### FORWARD LOOKING STATEMENTS

This report contains forward-looking statements regarding our business, financial condition, results of operations and prospects. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements, but are not deemed to represent an all-inclusive means of identifying forward-looking statements as denoted in this report. Additionally, statements concerning future matters are forward-looking statements.

Although forward-looking statements in this report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include, without limitation, those specifically addressed under the headings “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our annual report on Form 10-K for the year ended January 31, 2020, in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Form 10-Q and information contained in other reports that we file with the SEC. You are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this report.

We file reports with the SEC. The SEC maintains a website (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including us.

We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this report, except as required by law. Readers are urged to carefully review and consider the various disclosures made throughout the entirety of this quarterly report, which are designed to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.

References to “we,” “us,” “our” and words of like import refer to Nutriband Inc. and its subsidiaries unless the context indicates otherwise. Unless the context indicates otherwise, references to 4P Therapeutics relate to the operations of 4P Therapeutics LLC prior to our acquisition of 4P Therapeutics on August 1, 2018 and references to Pocono and Active Intelligence to operations of those companies prior to our acquisition of the PCP segment on August 31, 2020.

### Overview

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product is our abuse deterrent fentanyl transdermal system which we are developing to provide clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy combined with properties designed to help combat the opioid crisis by deterring the abuse and misuse of fentanyl patches. We believe that our abuse deterrent technology can also be utilized in transdermal patches to deter the abuse of other drugs and we are exploring follow-on applications. In addition, we are also exploring the development of generic transdermal patches and the application of our transdermal technology for the transdermal delivery of commercially available drugs or biologics that are typically delivered by injection.

The Company has no current plans to market our own consumer products. Following the acquisition of Pocono our focus has turned to contract manufacturing primarily in the Asia region with our partner Best Choice Inc. Best Choice Inc. currently works with a number of brands to whom we now provide consulting for and contract manufacturing services. The terms of our distribution agreement with Best Choice dated April 13, 2018 remain in place.

Year 1 minimum sales requirements have been restarted as of April 30, 2020 and the coronavirus impact on Best Choice will be monitored to decide if an allowance will be made again for the next 12-month minimums.

With our acquisition of 4P Therapeutics on August 1, 2018, our focus changed, and we plan to develop, and seek FDA approval on, a number of transdermal pharmaceutical products under development by 4P Therapeutics. As a result of the acquisition of 4P Therapeutics, we have a pipeline of potential products.

4P Therapeutics has not generated any revenue from any of its products under development. Rather, prior to our acquisition, 4P Therapeutics generated revenue to provide cash for its operations through contract research and development and related services for a small number of clients in the life sciences field on an as-needed basis. We are, for the near term, continuing this activity, although we do not anticipate that it will generate significant revenues or gross margin. Currently, there are no long-term contractual obligations for us, and either party can terminate the engagement at any time. During the nine months ended October 31, 2020, we experienced a significant decline in revenue from 4P Therapeutics’ largest customer, as a result of which our revenue from 4P Therapeutics was $127,625. 4P Therapeutics continues to operate and is currently working on a research agreement. 4P expects to execute a new lease in 2020 and to continue working on contracts with former customers. Our revenue from our South Korean distributor for the nine months ended October 31, 2020 was $357,484. Our cost of revenue for the nine months ended October 31, 2020 was $249,725. The Company expects the revenue from the South Korean distributor to increase substantially during the balance of the Company’s fiscal year. The Company also had revenue of $110,502 from the sale of transdermal patches from Pocono.

With the change in our focus, our capital requirement has increased substantially. The process of developing pharmaceutical products and submitting them for FDA approval is both time consuming and expensive, with no assurance of obtaining approval from the FDA to market our product in the United States. We have budgeted $5.0 million for research and development of our abuse deterrent fentanyl transdermal system, including clinical manufacturing and clinical trials that need to be completed in order to obtain FDA approval. However, the total cost could be substantially in excess of that amount. We do not presently have the funds to enable us to develop our lead product, and we are seeking funding from a proposed public offering for this purpose for which we have filed a registration statement. We cannot assure you that we will complete this offering and, even if we complete the offering, the net proceeds of the offering will not be sufficient to complete the development and clinical testing necessary for FDA approval for our lead product. In the event that we are not able to complete this offering, we may not be able to raise the funds to finance our operations, either through a private placement or a joint venture agreement or strategic relationship, and, if we cannot raise funds as required or enter into a joint venture or other strategic relationship, we may not be able to fund the development of our product pipeline. Any money we raise in a private placement will most likely be at a discount to the then current market price and the discount could be significant, which would result in significant dilution to our stockholders with no assurance any proceeds we raise will be sufficient for us to complete the development of our lead product.

On August 25, 2020, the Company formed Pocono Pharmaceuticals Inc.(“Pocono”), a wholly owned subsidiary of the Company. Effective August 31, 2020, the Company entered into a Purchase Agreement (“Agreement”) with Pocono Coated Products (“PCP”), the manufacturer of the Company’s transdermal products, pursuant to which PCP agreed to sell the Company certain of the assets and liabilities associated with its Transdermal, Topical, Cosmetic and Nutraceutical business (the “Business”), including all related equipment, intellectual property and trade secrets, cash balances, receivables, bank accounts and inventory. The net assets were contributed to Pocono. Included in the transaction, the Company acquired 100% of the membership interests of Active Intelligence LLC (“Active Intelligence”). The purchase price for the assets of the Business is (i) $6,000,000 paid in 608,519 shares of the Company’s common stock, based on the average price for the Company’s common stock for the previous 90 days as of the date of Closing (the “Shares”); (ii) a promissory note of the Company in the principal amount of $1,500,000, which is due upon the earlier of (a) twelve (12) months from issuance, or (b) immediately following a capital raise of no less than $4,000,000 and/or a public offering of no less than $4,000,000.

Michael Myers, the CEO of PCP, was elected to the Board of Directors of the Company at the annual meeting of shareholders of the Company held November 12, 2020.

The Agreement provides that it is effective August 31, 2020, on which date the parties also entered into an escrow agreement (the “Escrow Agreement”), with legal counsel serving as the escrow agent, providing for holding of the Note, certificate for the Shares, and the title to the Assets (held in a special purpose acquisition subsidiary) as collateral security for completion of all closing conditions under the Agreement. On that date, the parties also entered into a security agreement granting PCP a security interests in all proceeds of the Assets held as collateral under the Escrow Agreement.

### Results of Operations

### Three Months Ended October 31, 2020 and 2019

For the three months ended October 31, 2020, we generated revenue of $391,787 and our costs of revenues were $228,772, resulting in a gross profit of $163,015. For the three months ended October 31, 2019, we generated revenue of $82,567 and our cost of revenue was $106,126 resulting in negative gross profit of $23,359. We commenced generating revenues during the third quarter of 2018. Our revenue for the three months ended 2020 was derived from three sources – a continuation of research and development contracts of the type that 4P Therapeutics performed prior to our acquisition, which accounted for $ 44,581, sales of our consumer transdermal product to our South Korean distributor, which accounted for $236,714, which our distributor purchased for its preliminary marketing efforts since the product has not obtained regulatory approval for retail sales in South Korea, and sales of transdermal from our recent acquisition of $110,502. We anticipate that all of our revenue for the quarter ended January 31, 2021 will be generated from research and development contracts and sales of our consumer transdermal products. Our cost of revenue was $26,491 for our research and development contracts and $202,279 for the consumer patches. Since we do not have the funds for the development of our lead product, the 4P Therapeutics fixed costs are allocated to the contract services that we perform for clients. The Company moved from their 4P facilities, and many of the prior costs relating to the facility were not incurred. However, this resulted in our operations continuing to show a negative gross profit for the three months ended October 31, 2020.

For the three months ended October 31, 2020 our selling, general and administrative expenses were $203,976, primarily legal, accounting and payroll expense, compared to $307,015 in the three months ended October 31, 2019. The decrease from 2019 is primarily due to a decrease in payroll related expenses and non-cash compensation and decreases in legal fees during the three months.

As a result of the foregoing, we sustained a net loss of $42,569, or $(0.01) per share (basic and diluted) for the three months ended October 31, 2020, compared with a loss of $753,274 or $(0.14) per share (basic and diluted) for the three months ended October 31, 2019.

### Nine Months Ended October 31, 2020 and 2019

For the nine months ended October 31, 2020, we generated revenue of $595,611 and our costs of revenues were $420,648, resulting in gross profit of $174,963. For the nine months ended October 31, 2019, we generated revenue of $351,070 and our cost of revenue was $422,879 resulting in negative gross profit of $71,809. We commenced generating revenues during the third quarter of 2018. Our revenue for the nine months ended October 31, 2020 was derived from three sources – (1) a continuation of research and development contracts of the type that 4P Therapeutics performed prior to our acquisition, which accounted for $ 127,625, (2) sales of our consumer transdermal product to our South Korean distributor, which accounted for $357,484 which our distributor purchased for its preliminary marketing efforts since the product has not obtained regulatory approval for retail sales in South Korea, and (3) sales from our recent acquisition of transdermal patches, which accounted for $110,502. We anticipate that all of our revenue for the quarter ended October 31, 2020 will be generated from research and development contracts and sales of our consumer transdermal products. Our cost of revenue was $118,634 for our research and development contracts and $302,014 for the consumer patches. Since we do not have the funds for the development of our lead product, the 4P Therapeutics fixed costs are allocated to the contract services that we perform for clients. The Company moved from their 4P facilities, and many of the prior costs relating to the facility were not incurred.

For the nine months ended October 31, 2020 our selling, general and administrative expenses were $589,224, primarily legal, accounting and payroll expense, compared to $1,281,538 in the nine months ended October 31, 2019. The decrease from 2019 is primarily due to a decrease in payroll related expenses and non-cash compensation and decreases in legal fees during the nine months. Additionally, stock-based compensation was $38,000 for the nine months ended October 31, 2020 and $252,700 for the nine months ended July 31, 2019.

During the nine months ended October 31, 2020, we incurred gain on change in fair value of derivatives of $22,096 in connection with our October 2019 financing in which we raised gross proceeds of $250,000 and net proceeds of approximately $203,000 from the sale of convertible notes and warrants. We had no derivative expense during the nine months ended July 31, 2019.

We incurred interest expense of $206,836 for the nine months ended October 31, 2020 including the amortization of debt discounts of $202,500. We incurred interest expense of $1,559 in the nine months ended October 31, 2019. The Company also incurred a loss on extinguishment of debt of $12,500 in connection with conversion of debt to equity and a $69,131 early prepayment fee on the repayment of convertible debentures during the nine months ended October 31, 2020.

As a result of the foregoing, we sustained a net loss of $680,632, or $(0.12) per share (basic and diluted) for the nine months ended October 31, 2020, compared with a loss of $1,777,192, or $(0.33) per share (basic and diluted) for the nine months ended October 31, 2019.

### Liquidity and Capital Resources

As of October 31, 2020, we had $193,392 in cash and cash equivalents and a working capital deficiency of $2,230,240, as compared with cash and cash equivalents of $10,181 and working capital deficiency of $1,979,141 as of January 31, 2020. In March 2020, the Company repaid the convertible debt that the Company received in October 2019. The total payments, including a prepayment fee of $69,131 and accrued interest, was $345,565. In May 2019, the Company completed a private placement and received proceeds of $515,108. The increase in our working capital deficiency is primarily due to the issuance of a $1,500,000 note due in August 2021 in connection with the Company’s recent acquisition.

For the nine months ended October 31, 2020, we used cash of $213,909 in our operations. The principal adjustments to our net loss of $680,632 were amortization of debt discount of $202,500, depreciation and amortization of $83,562, and loss on extinguishment of debt and early prepayment fee on convertible debentures of $81,631 offset by a gain on change in fair value of derivative of $22,096.

For the nine months ended October 31, 2020, we had cash flows of $330,126 from financing activities, primarily $515,108 from gross proceeds from the sale of Units consisting of shares of common stock and warrants to purchase common stock offset by the repayment of convertible debt, including an early prepayment fee, of $339,131. The Company also received a PPP loan of $34,870 and a minority shareholder advanced the Company $160,000.

### Off Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

### Critical Accounting Policies

#### Going Concern

The Company’s consolidated financial statements for the nine months ended October 31, 2020 have been prepared on a going concern basis which contemplates the realization of assets and settlement of liabilities in the normal course of business. For the nine months ended October 31, 2020, the Company generated revenue of $595,611 on which it recorded cost of revenues of $420,648 and a loss from operations of $414,261. Subsequent to January 31, 2020, because of the lack of available cash and the decline in business resulting in part from the effects of the COVID-19 pandemic, the Company has temporarily closed its 4P facility, but 4P continues operations and expects to find new facilities before the end of its fiscal year Successful business operations and its transition to attaining profitability are dependent upon obtaining significant additional financing, generating revenue primarily from its professional services to cover its overhead, developing its products, and obtaining FDA approval to market any product it develops and implementing a marketing program for such products. These factors raise substantial doubt about the ability of the Company to continue as a going concern for a period of at least one year from the date of these financial statements. Without such financing, the Company may not be able to continue in business. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

#### Revenue Recognition

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. We adopted the guidance under the new revenue standards using the modified retrospective method effective February 1, 2018. Topic 606 requires us to recognize revenues when control of the promised goods or services and receipt of payment is probable. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied.

#### Revenue Service Types

The following is a description of our revenue service types, which include professional services and sales of goods:

- Professional services include the contract of research and development related services with our clients in the life sciences field on an as-needed basis. Deliverables primarily consist of detailed findings and conclusion reports provided to the client for each given research project engaged.
- Sales revenues are generated from the sale of our products. Upon the receipt of a purchase order, we have the order filled and shipped.

#### Contracts with Customers

A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration

Deferred Revenue

Deferred revenue is a liability related to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from a contract before achieving certain criteria that must be met for revenue to be recognized in accordance with GAAP. As of October 31, 2020, and January 31, 2020, the balance of deferred revenue was $118,017 and $—0-.

#### Performance Obligations

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract transaction price is allocated to each distinct prformance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company’s different revenue service types, the performance obligation is satisfied at different times. Our performance obligations include providing products and professional services in the area of research. We recognize product revenue performance obligations in most cases when the product has shipped to the customer. When we perform professional service work, we recognize revenue when we have the right to invoice the customer for the work completed, which typically occurs on a monthly basis for work performed during that month.

All revenue recognized in the statement of operations is considered to be revenue from contracts with customers.

#### Stock-Based Compensation

ASC 718, “Compensation — Stock Compensation,” prescribes accounting and reporting standards for all stock-based payment transactions in which employee services, and, since February 1, 2019, non-employee services, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Stock-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period).

#### New Financial Accounting Standards

Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the consolidated financial statements included herewith.

## Controls and procedures

As filed, 2,419 characters.

Disclosure controls and procedures.

As of the end of period covered by this report, we carried out an evaluation, with the participation of our chief executive officer and chief financial officer, of the effectiveness of our disclosure controls and procedures pursuant to Securities Exchange Act Rule 13a-15. Based upon that evaluation, we concluded that for reasons discussed in our annual report on Form 10-K for the year ended January 31, 2020, our disclosure controls and procedures are not effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms.

As reported in our Form 10-K, management has determined that our internal controls contain material weaknesses due to the absence of segregation of duties, as well as lack of qualified accounting personnel, excessive reliance on third party consultants for accounting, financial reporting and related activities, and the lack of any separation of duties. Because of our financial condition it is unlikely that we will be able to implement effective internal controls over financial reporting in the near future.

Until we generate significantly greater revenues and employ accounting personnel, it is doubtful that we will be able implement any system which provides us with any degree of internal controls over financial reporting. Due to the nature of this material weakness in our internal control over financial reporting, there is more than a remote likelihood that misstatements which could be material to our annual or interim financial statements could not be prevented or detected.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures may deteriorate.

Changes in internal controls over financial reporting.

No changes were made to our internal controls in the quarterly period covered by this report that have materially affected, or are reasonably likely materially to affect, our internal control over financial reporting.

### PART II—OTHER INFORMATION

### UPDATE

## Risk factors

As filed, 8,125 characters.

*You should carefully consider the risks described below together with all of the other information included in this prospectus before making an investment decision with regard to our securities. The risks set forth below are not the only risks facing us. Additional risks and uncertainties may exist that could also adversely affect our business, prospects or operations. If any of the following risks actually occurs, our business, financial condition or results of operations could be harmed. In that case, the trading price of our common stock could decline, and you may lose all or a significant part of your investment.*

***Because of a lack of funds, we have suspended our product development operations.***

Our business is the development of transdermal systems for the delivery of pharmaceuticals. The development of pharmaceutical products is highly cash intensive, and many early stage drug development companies are unable to raise sufficient cash to complete the development and testing of their products and obtain regulatory approval, with the result that they either obtain funding on very unfavorable terms, cease to conduct business or sell or license their intellectual property on unfavorable terms. As of October 31, 2020, we had $193,392 in cash and cash equivalents and a working capital deficiency of $2,230,240, as compared with cash and cash equivalents of $10,181 and working capital deficiency of $1,979,141 as of January 31, 2020. Because of the absence of any significant financing, we have suspended our development activities relating to our transdermal pharmaceutical products. Because of the anticipated lack of revenues until we have an approved product that we can market and the time required to obtain FDA approval, which can take many years, we must rely on our ability to raise money in the private or public equity market or enter into a joint venture relationship with a company that has the funds, the willingness and the ability to fund or obtain funds for the project that is the subject of the joint venture. In March 2020, we withdrew a registration statement relating to a proposed public offering. If we are able to raise funds or enter into a joint venture, it is likely that the term will not be favorable to us. We cannot assure you that we will be able to raise funds in a public or private financing or a joint venture, and, if we are unable to do so, we may cease operations.

***We are dependent on obtaining additional financing to enable us to pay off debt and to resume our product development operations.***

Our continued operations are substantially dependent on our ability to obtain additional financing to pay off substantial debt incurred in our August 31, 2020 acquisition of Pocono Coated Products, LLC and to provide us with the ability to resume product development operations and continue to finance our current operations and generate growth in our revenues.

**Our business is impacted by the following additional key risks:**

- Our business could be adversely affected by the effects of health pandemics or epidemics, including the recent outbreak of COVID-19, which was declared by the World Health Organization as a global pandemic, and is resulting in travel and other restrictions to reduce the spread of the disease, including state and local orders across the country, which, among other things, direct individuals to shelter at their places of residence, direct businesses and governmental agencies to cease non-essential operations at physical locations, prohibit certain non-essential gatherings, and order cessation of non-essential travel. The effects of these orders, government-imposed quarantines and measures we would take, such as work-from-home policies, may negatively impact productivity, disrupt our business and could delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition. Further, quarantines, shelter-in-place and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases could impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which could disrupt our supply chain.
- The FDA regulatory process may take longer and be more expensive than we anticipate without any assurance that we will obtain FDA approval.
- If we are not able to obtain FDA approval for our lead product, we may not have the resources to develop any other product, and we may not be able to continue in business.
- We may not be able to launch any products for which we receive FDA marketing approval.
- We may not be able to establish a distribution network for the marketing and sale of any products for which we receive FDA approval.
- We may not be able to establish manufacturing facilities in compliance with FDA good manufacturing practices or to enter into manufacturing agreements for the manufacture of our products in an FDA approved manufacturing facility.
- It may be necessary to us to enter into a joint venture or other strategic relationship in order to develop, perform clinical testing for, manufacture or market any of our proposed products. We may not be able to enter into such a relationship, and any relationship may not be successful, and the other party may have business interests and priorities that are different from ours.
- We are party to a settlement agreement with the SEC resulting from statements in our SEC filings that did not accurately reflect the FDA’s jurisdiction over our consumer products and did not disclose that we could not legally market these products in the United States. The settlement included a cease-and-desist order against violating the provisions of the Securities Exchange Act which require us to file accurate registration statements and annual reports with the SEC. Our failure to comply with our obligations under the settlement agreement could result in enforcement proceedings against us or our officers.
- We may not be able to protect our rights in our intellectual property, and we may be subject to intellectual property litigation which would be expensive and disruptive of our operations even if we eventually prevail on the merits.
- Unanticipated side effects or other adverse events resulting from the use of our product could require a recall of our products and, even if no recall is required, our reputation could be impaired by side effects.
- We may not be able to evaluate potential acquisition candidates, with the result that we may not be able to benefit from the acquisition or integrate the acquired business with our business. We have recently incurred an impairment charge as a result of an acquisition when the intellectual property assets of the acquired company were not as represented. We cannot assure you that we will not incur similar or other problems with any future acquisitions.
- We may fail to comply with all applicable laws and regulations relating to our product. We may have to change or adapt our operations in the event of changes in national, regional and local government regulations, taxation, controls and political and economic developments that affect our products and the market for our products;
- We may be unable to accurately estimate anticipated expenses, capital requirements and needs for additional financing;
- Best Choice or any other international distributor of our products may fail to comply with applicable laws;
- Best Choice or any other international distributor of our products may not be able to obtain any necessary regulatory approval necessary to market our product or, if they are able to obtain regulatory approval, they may not be successful in marketing our products;

Filed Dec 15, 2020.
Source: SEC EDGAR, the filing index for accession 0001213900-20-042751. Last ingested by Listed: Oct 24, 2026, 15:15 ET. No prices; not investment advice.
